2025-10-30 · 33 pg (0)

Q3 2025 Results

2025-08-07 · 33 pg (0)

Q2 2025 Results

2025-05-01 · 33 pg (0)

Q1 2025 Results

2024-10-30 · 33 pg

Q3 2024 Results

2024-08-08 · 33 pg

Q2 2024 Results

2024-04-30 · 33 pg

Q1 2024 Results

2025-02-19 · 33 pg (0)

FY24 2024 Results

2024-02-21 · 33 pg

FY2023 2023 Results

Rev $34.1B, EPS $5.80 (Rev +20% YoY from $28.5B)

📌 Mounjaro diabetes drug revenue surged to $5.2B in 2023 vs $1.0B in 2022, driving growth acceleration

2025-11-21 · 1 pg

New Board Director Elected

Carolyn R. Bertozzi, Ph.D elected to board effective Dec 8, 2025

2025-10-30 · 1 pg

Q3 Earnings

Q3 2025 financial results announced

2025-08-20 · 3 pg

Multi-Tranche Debt Offering

$6.75B notes issued across 7 tranches, rates 4.0%-5.65%

2025-08-07 · 1 pg

Q2 Earnings

Q2 2025 financial results for quarter ended June 30, 2025

2025-05-08 · 1 pg

Annual Shareholder Meeting

846.7M shares voted (89% turnout), classified board elimination failed

2025-05-01 · 1 pg

Q1 2025 Earnings

Q1 2025 financial results announced

2025-02-12 · 3 pg

Multi-Tranche Bond Issuance

$6.46B notes across 6 tranches, rates 4.55%-5.60%

2025-02-06 · 1 pg

Q4 2024 Earnings

Financial results for quarter and year ended December 31, 2024

2025-01-14 · 1 pg

2025 Guidance Update

Updated 2024 earnings guidance and 2025 revenue guidance at JPM Conference

2024-11-19 · 2 pg

Board Changes - New Director Added, Director Resigned

Jon Moeller (P&G CEO) elected to board Dec 1, Karen Walker resigned Dec 31

2024-10-30 · 1 pg

Q3 Earnings

Q3 2024 financial results for quarter ended September 30, 2024

2024-09-09 · 1 pg

CFO Appointed

Lucas Montarce elected EVP/CFO, $1M base salary

2024-08-16 · 1 pg

Director Retirement

Dr. Marschall S. Runge retired from Board effective August 31, 2024

2024-08-14 · 3 pg

Debt Offering

$5B notes offering across 5 series, rates 4.15%-5.20%

2024-08-08 · 1 pg

Q2 2024 Earnings

Financial results for quarter ended June 30, 2024

2024-07-10 · 1 pg

CFO Departed, Interim CFO Appointed

Anat Ashkenazi resigned as CFO, Gordon Brooks named interim CFO effective July 15, 2024

2024-06-05 · 1 pg

CFO Resigned

Anat Ashkenazi out, serving through July 2024

2024-05-09 · 2 pg

Annual Shareholder Meeting

90% turnout, 4 directors elected, compensation approved, governance proposals failed

2024-04-30 · 1 pg

Q1 2024 Earnings

Q1 2024 financial results announced

2024-02-09 · 3 pg

Debt Offering

$6.5B multi-tranche notes, rates 4.5%-5.1%